Your browser doesn't support javascript.
loading
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
Necchi, Andrea; Lo Vullo, Salvatore; Mariani, Luigi; Raggi, Daniele; Giannatempo, Patrizia; Calareso, Giuseppina; Togliardi, Elena; Crippa, Flavio; Di Genova, Nicola; Perrone, Federica; Colecchia, Maurizio; Paolini, Biagio; Pelosi, Giuseppe; Nicolai, Nicola; Procopio, Giuseppe; Salvioni, Roberto; De Braud, Filippo G.
Affiliation
  • Necchi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy. andrea.necchi@istitutotumori.mi.it.
  • Lo Vullo S; Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Mariani L; Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Raggi D; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy.
  • Giannatempo P; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy.
  • Calareso G; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Togliardi E; Pharmacy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Crippa F; Nuclear Medicine and PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Di Genova N; Clinical Trials Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Perrone F; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Colecchia M; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Paolini B; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Pelosi G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Nicolai N; Università degli Studi di Milano, Milano, Italy.
  • Procopio G; Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Salvioni R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy.
  • De Braud FG; Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Invest New Drugs ; 34(2): 236-42, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26873642
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Azepines / Urinary Bladder Neoplasms / Urothelium / Protein Kinase Inhibitors / Aurora Kinase A Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2016 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Azepines / Urinary Bladder Neoplasms / Urothelium / Protein Kinase Inhibitors / Aurora Kinase A Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2016 Document type: Article Affiliation country: Country of publication: